The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.
about
Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitroHigh throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human MacrophagesPlacental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
P2860
The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@en
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@nl
type
label
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@en
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@nl
prefLabel
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@en
The inhibitor of cyclin-depend ...... s potent antiviral properties.
@nl
P2093
P2860
P50
P356
P1476
The inhibitor of cyclin-depend ...... ts potent antiviral properties
@en
P2093
Borivoj Vojtesek
Gavin Wg Wilkinson
Jitka Holcakova
Miroslav Strnad
Peter Tomasec
Roman Hrstka
P2860
P304
P356
10.3851/IMP1460
P577
2010-01-05T00:00:00Z